About NeuroDelta Ltd

 

NeuroDelta Ltd is a Leeds based research and development company that uses in silico identification of protein-protein interactions for subsequent development as models for drug and diagnostic discovery. The original NeuroDelta concept was developed by our founder Dr Nat Milton in May 2003 when the original company was formed, based on his expertise in Alzheimer's research. The current in silico bioinformatic research and development activity has focussed on the in identification and characterization of novel targets for anti-amyloid plus other protein targeting development activities, including targeting proteins involved in enzyme processing of endogenous mediators of amyloid toxicity. Recent work has also involved identification of novel interactions of KiSS-1 metastasis suppressor protein products with Alzheimer's associated proteins.

 

A UK patent for the use of kissorphin peptides in the treatment of Alzheimer's disease, Creutzfeldt jakob disease and diabetes mellitus (Milton 2017) has been granted to the University of Roehampton and patent applications have also previously been filed by Insight Biotechnology Ltd based on Dr Milton's work using in silico and in vitro techniques. Amongst the compounds identified are Amyloid-ß anti-sense peptides, Phosphorylated Amyloid-ß and KiSS-1 metastasis suppressor protein derived peptides. Amongst the compounds developed from these techniques is the R9 peptide, which inhibits catalase interactions with amyloid-ß fibrils, plus the Kisspeptin and Kissorphin peptides, which inhibit amyloid-ß, amylin and prion protein fragment induced neurotoxicity in vitro.

 

NeuroDelta Ltd will undertake commercial screening for the identification of novel protein-protein interactions and interested parties should contact the company directly (info@neurodelta.uk) directly for details of the potential services that can be provided.